CA-TAULIA
21.11.2023 09:01:31 CET | Business Wire | Press release
Taulia, a leading provider of working capital management solutions, has partnered with Mastercard to launch Taulia Virtual Cards. The new solution provides businesses with additional working capital management advantages, including the ability to maximize cash flow and minimize payment uncertainty. Following Taulia Virtual Cards’ seamless integration across SAP ERP solutions, including SAP S/4HANA and other major enterprise resource planning (ERP) platforms, corporates can streamline previously cumbersome payment-related tasks more effectively and affordably.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231121680451/en/
Initially, two major banks - Degussa Bank and HSBC - are set to participate. Taulia customers will benefit through their existing issuer relationships, meaning customers can deploy virtual cards and extend the current benefits offered by their own banks through Taulia, while also enjoying the speed, controls, and efficiency of virtual card payments. This “bring your own bank” capability is made possible by Taulia’s integration with Mastercard’s innovative virtual card platform, which is connected with more than 80 banks globally.
This partnership will allow Taulia to expand its working capital solutions for businesses by leveraging virtual cards generated through Mastercard upon request, providing significant time and cost savings to corporates seeking more consumer-grade user experiences in their enterprise platforms.
Through the tightly integrated virtual card experience, businesses benefit from greater spend control and more options to pay suppliers efficiently. On the other end, suppliers gain improved cash flow and enhanced visibility, alleviating friction across B2B transactions.
Danielle Weinblatt, Chief Product Officer, Taulia, commented: “We are delighted to be partnering with Mastercard, doubling down on our commitment to transform the world of global trade and commerce by bringing our customers a fully embedded working capital management solution that prioritizes the customer experience.”
Rebecca Meeker, Senior Vice President, Global Partnerships and Segments, Mastercard, commented: “Fragmented B2B payment practices have held businesses back for too long. Virtual cards accelerate automation and support cash flow through increased access to working capital, which is why Mastercard is thrilled to work with Taulia and its banking partners to extend the benefits of virtual cards while prioritizing customer experience.”
Arati Kurien, Global Head of Commercial Cards Product Management, HSBC, commented: “We’re pleased to be embracing innovation through our partnerships with Taulia and Mastercard, which will now provide our clients with an integrated virtual card payment solution within the Taulia platform. Embedding HSBC’s financial services into the systems that our clients use day to day is a key focus for us.”
Matthias Weiß, Board Member, Degussa Bank AG, commented: “We are very excited to provide our customers an SAP-integrated virtual credit card solution and are looking forward to a successful partnership with Taulia to grow our German procurement footprint.”
ENDS
About Taulia
Taulia is a fintech provider of working capital management solutions headquartered in San Francisco, California. Taulia helps companies access value tied up in their payables, receivables, and inventory. Taulia's platform and network of more than 3 million businesses enables customers to execute their working capital strategies, support their suppliers with early payment, and contribute to building sustainable supply chains. Taulia processes more than $500 billion each year and is trusted by the world’s largest companies, including Airbus, AstraZeneca, and Nissan. In March 2022, Taulia became part of SAP. For more information, please visit www.taulia.com.
About Degussa Bank
Degussa Bank AG is a retail bank based in Frankfurt/Main, Germany. It offers a wide range of financial services to employees of partner companies (B2C) as well as to corporates (B2B). Degussa Bank is a leading B2B Commercial card issuer in Germany and Austria. Degussa Bank card solution rely on customer centric solutions with a high standard of data management with several integration opportunities to T&E, Accounting- and ERP-Systems. Degussa Bank has over 20 years’ experience in card issuing and over 10 years especially with virtual cards.
About HSBC
HSBC Holdings plc, is a public limited company incorporated in England. Headquartered in London, HSBC is listed on the London, Hong Kong, New York, and Bermuda stock exchanges. The entities that form the HSBC Group provide a comprehensive range of financial services. Our international network comprises some 3,500+ offices in 62 countries and territories in Europe, the Asia-Pacific region, the Americas, the Middle East, and Africa. We serve over 39 million customers through three global businesses: Wealth and Personal Banking (‘WPB'), Commercial Banking ('CMB'), and Global Banking and Markets ('GBM'). HSBC offers a wide range of services to all sizes of business, from multinationals to small and medium-sized enterprises. Services include traditional corporate banking facilities, such as bank accounts, money transmission services, overdrafts, short and medium-term loans, treasury and foreign exchange, trade services, and global cash management, including corporate cards.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231121680451/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
